ASCO GI: Targeted Agent Slows Neuroendocrine Tumors

Loading...

Sign in or sign up now!
Alert icon
Upgrade to the latest Flash Player for improved playback performance. Upgrade now or more info.
291 views
Loading...
Alert icon
Sign in or sign up now!
Alert icon

Uploaded by on Mar 2, 2010

ORLANDO -- Patients with progressive pancreatic neuroendocrine tumors lived twice as long without progression when treated with sunitinib (Sutent) compared with placebo, data from a French clinical trial showed.

Median overall survival had not been reached in the sunitinib arm, but sunitinib treatment was associated with a 60% reduction in hazard ratio compared with placebo. More than 90% of patients in the sunitinib group remained alive at six months, Eric Raymond, MD, reported here at the Gastrointestinal Cancers Symposium.

Category:

News & Politics

Tags:

License:

Standard YouTube License

  • likes, 1 dislikes

Link to this comment:

Share to:
see all

All Comments (2)

Sign In or Sign Up now to post a comment!
  • Here is the concern in lab studies....on does sutnet fule mets....

    Also, its important to clearly understand what happens when the drug stops working! It happened to me with another drug! hell!

  • This is an interesting video...question and should have beeb disclosed, does Dr Raymond have a relationship with the company? That is always a concern for me...

    btw, your hair turns silver white, not GREY......! I did pazopanib...

    finally this md should have asked re: risks of VEGF inhibitors potentially spreading cancer when they stop working!

  • Loading comment...
Loading...

Alert icon
0 / 00Unsaved Playlist Return to active list
    1. Your queue is empty. Add videos to your queue using this button:
      or sign in to load a different list.
    Loading...Loading...Saving...
    • Clear all videos from this list
    • Learn more